| Year |
Citation |
Score |
| 2019 |
Ogiya D, Müller L, Verselis SJ, Schaal H, Abiatari I, Stenstrom AM, Nicholas CA, Daley JF, Chu MP, Dorfman DM, Pilarski LM, Hideshima T, Anderson KC, Adamia S. Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy Blood. 134: 1804-1804. DOI: 10.1182/blood-2019-131775 |
0.337 |
|
| 2019 |
Adamia S, Ogiya D, Abiatari I, Verselis SJ, Chu MP, Dorfman DM, Pilarski LM, Hideshima T, Anderson KC. Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches Blood. 134: 3079-3079. DOI: 10.1182/blood-2019-131243 |
0.33 |
|
| 2017 |
He Z, Kannan N, Nemirovsky O, Chen H, Connell M, Taylor B, Jiang J, Pilarski LM, Fleisch MC, Niederacher D, Pujana MA, Eaves CJ, Maxwell CA. BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells. Oncotarget. PMID 28427147 DOI: 10.18632/Oncotarget.15688 |
0.309 |
|
| 2017 |
Sanyal R, Polyak MJ, Zuccolo J, Puri M, Deng L, Roberts L, Zuba A, Storek J, Luider JM, Sundberg EM, Mansoor A, Baigorri E, Chu MP, Belch AR, Pilarski LM, et al. MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells. Immunology and Cell Biology. PMID 28303902 DOI: 10.1038/icb.2017.18 |
0.408 |
|
| 2016 |
Martin LD, Harizanova J, Mai S, Belch AR, Pilarski LM. FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4. Genes, Chromosomes & Cancer. PMID 27509849 DOI: 10.1002/Gcc.22394 |
0.614 |
|
| 2016 |
Chu MP, Venner CP, Sandhu I, Baigorri E, Kriangkum J, Hewitt JD, Belch A, Pilarski LM. Ex Vivo Modeling of Multiple Myeloma Provides Basis for Studying Treatment Combinations and Immunotherapy Blood. 128: 2113-2113. DOI: 10.1182/blood.v128.22.2113.2113 |
0.357 |
|
| 2013 |
Martin LD, Harizanova J, Righolt CH, Zhu G, Mai S, Belch AR, Pilarski LM. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma. Genes, Chromosomes & Cancer. 52: 523-37. PMID 23460268 DOI: 10.1002/Gcc.22049 |
0.578 |
|
| 2012 |
Martin LD, Harizanova J, Zhu G, Righolt CH, Belch AR, Mai S, Pilarski LM. Differential positioning and close spatial proximity of translocation-prone genes in nonmalignant B-cells from multiple myeloma patients. Genes, Chromosomes & Cancer. 51: 727-42. PMID 22489023 DOI: 10.1002/Gcc.21959 |
0.633 |
|
| 2011 |
Toman I, Loree J, Klimowicz AC, Bahlis N, Lai R, Belch A, Pilarski L, Reiman T. Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics. Leukemia & Lymphoma. 52: 659-67. PMID 21438833 DOI: 10.3109/10428194.2010.548535 |
0.47 |
|
| 2010 |
Pilarski LM, Pilarski PM, Belch AR. Multiple myeloma may include microvessel endothelial cells of malignant origin. Leukemia & Lymphoma. 51: 592-7. PMID 20233053 DOI: 10.3109/10428191003661860 |
0.326 |
|
| 2010 |
Martin LD, Belch AR, Pilarski LM. Promiscuity of translocation partners in multiple myeloma. Journal of Cellular Biochemistry. 109: 1085-94. PMID 20127714 DOI: 10.1002/jcb.22499 |
0.595 |
|
| 2010 |
Martin LD, Harizanova J, Zhu G, Belch A, Mai S, Pilarski LM. Cancer-Specific Nuclear Positioning of Translocation Prone Gene Loci In Non-Malignant B-Cells From Patients with Multiple Myeloma Blood. 116: 783-783. DOI: 10.1182/Blood.V116.21.783.783 |
0.672 |
|
| 2009 |
Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, ... ... Pilarski L, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 23: 2210-21. PMID 19798094 DOI: 10.1038/Leu.2009.174 |
0.301 |
|
| 2009 |
Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 57: 239-47. PMID 19001640 DOI: 10.1369/Jhc.2008.952200 |
0.364 |
|
| 2008 |
Pilarski LM, Baigorri E, Mant MJ, Pilarski PM, Adamson P, Zola H, Belch AR. Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab. Clinical Medicine. Oncology. 2: 275-87. PMID 21892289 |
0.44 |
|
| 2008 |
Adamia S, Reichert AA, Kuppusamy H, Kriangkum J, Ghosh A, Hodges JJ, Pilarski PM, Treon SP, Mant MJ, Reiman T, Belch AR, Pilarski LM. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. Blood. 112: 5111-21. PMID 18815290 DOI: 10.1182/blood-2008-02-141770 |
0.36 |
|
| 2008 |
Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR, Pilarski LM. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood. 112: 2935-45. PMID 18535198 DOI: 10.1182/Blood-2008-02-142430 |
0.657 |
|
| 2008 |
Evans R, Naber C, Steffler T, Checkland T, Keats J, Maxwell C, Perry T, Chau H, Belch A, Pilarski L, Reiman T. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leukemia & Lymphoma. 49: 559-69. PMID 18297535 DOI: 10.1080/10428190701824544 |
0.386 |
|
| 2008 |
Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R, Reiman T. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. British Journal of Haematology. 140: 295-302. PMID 18076711 DOI: 10.1111/j.1365-2141.2007.06913.x |
0.356 |
|
| 2007 |
Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, ... ... Pilarski LM, et al. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Experimental Hematology. 35: 1366-75. PMID 17761288 DOI: 10.1016/J.Exphem.2007.05.022 |
0.378 |
|
| 2007 |
Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A. Targeting aurora kinases as therapy in multiple myeloma. Blood. 109: 3915-21. PMID 17213289 DOI: 10.1182/Blood-2006-07-037671 |
0.356 |
|
| 2007 |
Kirshner J, Thulien KJ, Martin LD, Marun CD, Reiman T, Belch AR, Pilarski LM. A Unique Pre-Clinical Model Providing Access to a Drug Resistant Population within the Multiple Myeloma Stem Cell Niche in a Novel 3-D Culture System for Bone Marrow. Blood. 110: 547-547. DOI: 10.1182/Blood.V110.11.547.547 |
0.614 |
|
| 2007 |
Sidhu R, Steffler T, Hipperson G, Jung M, Fung J, Pilarski LM, Belch AR, Reiman T. Pre-Clinical Validation of Polo-Like Kinase 1 as a Therapeutic Target in Multiple Myeloma with the Selective Inhibitor BI2536. Blood. 110: 2514-2514. DOI: 10.1182/blood.v110.11.2514.2514 |
0.318 |
|
| 2006 |
Kriangkum J, Taylor BJ, Strachan E, Mant MJ, Reiman T, Belch AR, Pilarski LM. Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery. Blood. 107: 2920-7. PMID 16317092 DOI: 10.1182/blood-2005-09-3613 |
0.318 |
|
| 2006 |
Thulien KJ, Reiman T, Belch AR, Booth J, Pilarski LM. Quantitative Detection Using SYBR Green of Residual Disease in Myeloma Patients Treated with Revlimid or Velcade. Blood. 108: 5102-5102. DOI: 10.1182/BLOOD.V108.11.5102.5102 |
0.303 |
|
| 2006 |
Taylor BJ, Baigorri E, Hay M, Reiman T, Belch AR, Pilarski LM. Genomic Instability in Multiple Myeloma: Inducible Transfectants Provide a Model To Define the Role of RHAMM and Centrosome/Mitotic Spindle Stability in Myelomagenesis. Blood. 108: 5037-5037. DOI: 10.1182/BLOOD.V108.11.5037.5037 |
0.335 |
|
| 2005 |
Kriangkum J, Taylor BJ, Reiman T, Belch AR, Pilarski LM. Origins of Waldenstrom's macroglobulinemia: does it arise from an unusual B-cell precursor? Clinical Lymphoma. 5: 217-9. PMID 15794851 |
0.357 |
|
| 2005 |
Santos DD, Ho AW, Tournilhac O, Leleu X, Hatjiharrisi E, Xu L, Tassone P, Neri P, Hunter Z, Chemaly MA, Branagan A, Manning R, Patterson C, Adamia S, Kriangkum J, ... ... Pilarski L, et al. Establishment of a Waldenstrom’s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice. Blood. 106: 979-979. DOI: 10.1182/Blood.V106.11.979.979 |
0.524 |
|
| 2005 |
Debes-Marun C, Belch AR, Pilarski LM. Circulating B Lymphocytes from Patients with Multiple Myeloma Harbour T(4;14) Translocations and Chromosome 13 Deletions. Blood. 106: 500-500. DOI: 10.1182/BLOOD.V106.11.500.500 |
0.358 |
|
| 2005 |
Thulien KJ, Blech AR, Reiman T, Pilarski LM. Molecular Quantitation of Minimal Residual Disease in Multiple Myeloma Patients Achieving Complete Remission after Treatment with Revlimid or Velcade. Blood. 106: 3487-3487. DOI: 10.1182/BLOOD.V106.11.3487.3487 |
0.312 |
|
| 2005 |
Kriangkum J, Taylor BJ, Strachan E, Reiman T, Belch AR, Mant MJ, Pilarski LM. Clonotypic IgG B Cells in Waldenstrom Macroglobulinemia Cells Are Derived from Multiple Post-Transformed B Cells That Have Undergone Isotype Switch Recombination. Blood. 106: 1002-1002. DOI: 10.1182/BLOOD.V106.11.1002.1002 |
0.36 |
|
| 2004 |
Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood. 104: 2134-42. PMID 14764523 DOI: 10.1182/blood-2003-11-4024 |
0.426 |
|
| 2004 |
Taylor BJ, Ye M, Strachan ER, Tiffinger TM, Belch AR, Pilarski LM. Clonal Analysis of IgM Cells in Multiple Myeloma Patients Suggests the Co-Existence of Normal and Malignant Arms of the Myeloma Clone. Blood. 104: 1415-1415. DOI: 10.1182/blood.v104.11.1415.1415 |
0.317 |
|
| 2004 |
Adamia S, Reiman T, Mant MJ, Belch AR, Pilarski LM. Aberrant Intronic Splicing of the Hyaluronan Synthase 1 Gene (HAS1) in Multiple Myeloma: A Biologically Relevant Marker That Predicts for Poor Survival. Blood. 104: 1413-1413. DOI: 10.1182/BLOOD.V104.11.1413.1413 |
0.308 |
|
| 2004 |
Kriangkum J, Taylor BJ, Strachan ER, Treon SP, Mant MJ, Reiman T, Belch AR, Pilarski LM. Mutator Genes UDG and AID Appear To Be Normal in Class-Switch Deficient and Clonally Homogeneous Waldenstrom’s Macroglobulinemias Having Either Germline or Hypermutated Clonotypic IgH VDJ. Blood. 104: 1359-1359. DOI: 10.1182/BLOOD.V104.11.1359.1359 |
0.323 |
|
| 2003 |
Kriangkum J, Taylor BJ, Mant MJ, Treon SP, Belch AR, Pilarski LM. The malignant clone in Waldenstrom's macroglobulinemia. Seminars in Oncology. 30: 132-5. PMID 12720122 DOI: 10.1053/sonc.2003.50061 |
0.444 |
|
| 2002 |
Pilarski LM, Belch AR. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3198-204. PMID 12374689 |
0.406 |
|
| 2002 |
Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KC. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: 72-81. PMID 11924912 |
0.685 |
|
| 2002 |
Pilarski LM, Seeberger K, Coupland RW, Eshpeter A, Keats JJ, Taylor BJ, Belch AR. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Experimental Hematology. 30: 221-8. PMID 11882359 |
0.337 |
|
| 2001 |
Zalai CV, Kolodziejczyk MD, Pilarski L, Christov A, Nation PN, Lundstrom-Hobman M, Tymchak W, Dzavik V, Humen DP, Kostuk WJ, Jablonsky G, Pflugfelder PW, Brown JE, Lucas A. Increased circulating monocyte activation in patients with unstable coronary syndromes. Journal of the American College of Cardiology. 38: 1340-7. PMID 11691505 DOI: 10.1016/S0735-1097(01)01570-4 |
0.331 |
|
| 2001 |
Reiman T, Seeberger K, Taylor BJ, Szczepek AJ, Hanson J, Mant MJ, Coupland RW, Belch AR, Pilarski LM. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood. 98: 2791-9. PMID 11675353 |
0.643 |
|
| 2001 |
Szczepek AJ, Belch AR, Pilarski LM. Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: potential for autocrine and paracrine networks. Experimental Hematology. 29: 1076-81. PMID 11532348 DOI: 10.1016/S0301-472X(01)00682-8 |
0.572 |
|
| 2000 |
Gares SL, Pilarski LM. Balancing thymocyte adhesion and motility: a functional linkage between beta1 integrins and the motility receptor RHAMM. Developmental Immunology. 7: 209-25. PMID 11097213 |
0.735 |
|
| 2000 |
Lopes de Menezes DE, Pilarski LM, Belch AR, Allen TM. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochimica Et Biophysica Acta. 1466: 205-20. PMID 10825443 DOI: 10.1016/S0005-2736(00)00203-0 |
0.43 |
|
| 2000 |
Pilarski LM, Giannakopoulos NV, Szczepek AJ, Masellis AM, Mant MJ, Belch AR. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease Clinical Cancer Research. 6: 585-596. PMID 10690543 |
0.701 |
|
| 2000 |
Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice Blood. 95: 1056-1065. DOI: 10.1182/BLOOD.V95.3.1056.003K26_1056_1065 |
0.314 |
|
| 1999 |
Gares SL, Pilarski LM. Beta1-integrins control spontaneous adhesion and motility of human progenitor thymocytes and regulate differentiation-dependent expression of the receptor for hyaluronan-mediated motility. Scandinavian Journal of Immunology. 50: 626-34. PMID 10607311 |
0.748 |
|
| 1999 |
Pilarski LM, Mant MJ, Belch AR. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone. Leukemia & Lymphoma. 32: 199-210. PMID 10037018 DOI: 10.3109/10428199909167381 |
0.351 |
|
| 1999 |
Lopes de Menezes DE, Kirchmeier MJ, Gagne J, Pilarski LM, Allen TM. Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells Journal of Liposome Research. 9: 199-228. DOI: 10.3109/08982109909024786 |
0.37 |
|
| 1999 |
Pilarski LM, Pruski E, Wizniak J, Paine D, Seeberger K, Mant MJ, Brown CB, Belch AR. Potential Role for Hyaluronan and the Hyaluronan Receptor RHAMM in Mobilization and Trafficking of Hematopoietic Progenitor Cells Blood. 93: 2918-2927. DOI: 10.1182/BLOOD.V93.9.2918.409K19_2918_2927 |
0.305 |
|
| 1999 |
Crainie M, Belch AR, Mant MJ, Pilarski LM. Overexpression of the Receptor for Hyaluronan-Mediated Motility (RHAMM) Characterizes the Malignant Clone in Multiple Myeloma: Identification of Three Distinct RHAMM Variants Blood. 93: 1684-1696. DOI: 10.1182/BLOOD.V93.5.1684.405K22_1684_1696 |
0.382 |
|
| 1999 |
Crainie M, Belch AR, Mant MJ, Pilarski LM. Overexpression of the Receptor for Hyaluronan-Mediated Motility (RHAMM) Characterizes the Malignant Clone in Multiple Myeloma: Identification of Three Distinct RHAMM Variants Blood. 93: 1684-1696. DOI: 10.1182/blood.v93.5.1684 |
0.382 |
|
| 1999 |
Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC. Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone Blood. 93: 1287-1298. DOI: 10.1182/BLOOD.V93.4.1287.404K14_1287_1298 |
0.39 |
|
| 1999 |
Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC. Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone Blood. 93: 1287-1298. DOI: 10.1182/blood.v93.4.1287 |
0.39 |
|
| 1998 |
Gares SL, Giannakopoulos N, MacNeil D, Faull RJ, Pilarski LM. During human thymic development, beta 1 integrins regulate adhesion, motility, and the outcome of RHAMM/hyaluronan engagement. Journal of Leukocyte Biology. 64: 781-90. PMID 9850161 DOI: 10.1002/Jlb.64.6.781 |
0.745 |
|
| 1998 |
Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood. 92: 2844-55. PMID 9763569 |
0.671 |
|
| 1998 |
Pilarski L, Yatscoff R, Murphy G, Belch A. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers Leukemia. 12: 505-509. PMID 9557608 DOI: 10.1038/Sj.Leu.2400984 |
0.36 |
|
| 1997 |
Pilarski LM, Szczepek AJ, Belch AR. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood. 90: 3751-9. PMID 9345062 |
0.639 |
|
| 1997 |
Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood. 89: 1824-33. PMID 9057669 DOI: 10.1182/Blood.V89.5.1824 |
0.699 |
|
| 1997 |
Pilarski LM, Masellis-Smith A, Szczepek A, Mant MJ, Belch AR. Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leukemia & Lymphoma. 22: 375-83. PMID 8882950 DOI: 10.3109/10428199609054775 |
0.377 |
|
| 1997 |
Szczepek A, Mant M, Belch A, Pilarski LM. Circulating CD19+ cells in multiple myeloma are clonaly related to the end stage malignant plasma cells in the bone marrow Immunology Letters. 56: 327. DOI: 10.1016/S0165-2478(97)86322-5 |
0.644 |
|
| 1996 |
Masellis-Smith A, Belch A, Mant M, Turley E, Pilarski L. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44 Blood. 87: 1891-1899. DOI: 10.1182/Blood.V87.5.1891.Bloodjournal8751891 |
0.549 |
|
| 1995 |
Pilarski LM, Laderoute MP, Rutkowski D. Apoptosis among CD45RA-/low CD3+ progeny accompanies differentiation of human multinegative thymocytes. Scandinavian Journal of Immunology. 41: 237-46. PMID 7871383 DOI: 10.1111/j.1365-3083.1995.tb03559.x |
0.377 |
|
| 1995 |
Pilarski LM, Paine D, McElhaney JE, Cass CE, Belch AR. Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging. American Journal of Hematology. 49: 323-35. PMID 7639278 DOI: 10.1002/AJH.2830490411 |
0.301 |
|
| 1995 |
Bergsagel PL, Masellis Smith A, Belch AR, Pilarski LM. The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. Current Topics in Microbiology and Immunology. 194: 17-24. PMID 7534667 DOI: 10.1007/978-3-642-79275-5_3 |
0.347 |
|
| 1995 |
Pilarski LM, Masellis-Smith A, Belch AR, Yang B, Savani RC, Turley EA. RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy? Leukemia & Lymphoma. 14: 363-74. PMID 7529076 DOI: 10.3109/10428199409049691 |
0.469 |
|
| 1995 |
Bergsagel P, Smith A, Szczepek A, Mant M, Belch A, Pilarski L. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain [published erratum appears in Blood 1995 Jun 1;85(11):3365] Blood. 85: 436-447. DOI: 10.1182/Blood.V85.2.436.Bloodjournal852436 |
0.722 |
|
| 1995 |
Bergsagel P, Smith A, Szczepek A, Mant M, Belch A, Pilarski L. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain [published erratum appears in Blood 1995 Jun 1;85(11):3365] Blood. 85: 436-447. DOI: 10.1182/blood.v85.2.436.436 |
0.474 |
|
| 1994 |
Deans JP, Ledbetter JA, Pilarski LM. Differential modulation of human multinegative (CD3-4-8-) thymocyte proliferation by monoclonal antibodies to CD45RA or to CD45. Immunology and Cell Biology. 72: 292-9. PMID 7806262 DOI: 10.1038/icb.1994.44 |
0.316 |
|
| 1994 |
Yacyshyn BR, Pilarski LM. Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease. Gut. 34: 1698-704. PMID 7506695 DOI: 10.1136/gut.34.12.1698 |
0.399 |
|
| 1994 |
Pilarski L, Belch A. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma Blood. 83: 724-736. DOI: 10.1182/Blood.V83.3.724.724 |
0.486 |
|
| 1994 |
Szczepek AJ, Belch AR, Pilarski LM. Interleukin-6 (IL-6) and interferon gamma (IFNγ) expression in peripheral blood lymphocytes (PBMC) from multiple myeloma patients Cytokine. 6: 570. DOI: 10.1016/1043-4666(94)90269-0 |
0.566 |
|
| 1993 |
Pilarski LM. Adhesive interactions in thymic development: does selective expression of CD45 isoforms promote stage-specific microclustering in the assembly of functional adhesive complexes on differentiating T lineage lymphocytes? Immunology and Cell Biology. 59-69. PMID 8436412 DOI: 10.1038/icb.1993.6 |
0.346 |
|
| 1993 |
Jensen GS, Belch AR, Mant MJ, Ruether BA, Yacyshyn BR, Pilarski LM. Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. American Journal of Hematology. 43: 29-36. PMID 7686332 DOI: 10.1002/AJH.2830430108 |
0.334 |
|
| 1993 |
Jensen GS, Belch AR, Mant MJ, Ruether BA, Pilarski LM. Expression of multiple adhesion molecules on circulating monoclonal B cells in myeloma. Current Topics in Microbiology and Immunology. 182: 187-93. PMID 1283366 DOI: 10.1007/978-3-642-77633-5_22 |
0.314 |
|
| 1993 |
Jensen GS, Belch AR, Kherani F, Mant MJ, Ruether BA, Pilarski LM. Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CD11b on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Scandinavian Journal of Immunology. 36: 843-53. PMID 1281335 DOI: 10.1111/j.1365-3083.1992.tb03146.x |
0.455 |
|
| 1993 |
Pilarski LM. A requirement for antigen-specific helper T cells in the generation of cytotoxic T cells from thymocyte precursors. The Journal of Experimental Medicine. 145: 709-25. PMID 233910 DOI: 10.1084/JEM.145.3.709 |
0.305 |
|
| 1993 |
Turley E, Belch A, Poppema S, Pilarski L. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes Blood. 81: 446-453. DOI: 10.1182/BLOOD.V81.2.446.BLOODJOURNAL812446 |
0.397 |
|
| 1992 |
Jensen GS, Mant MJ, Pilarski LM. Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient. American Journal of Hematology. 41: 199-208. PMID 1384318 DOI: 10.1002/AJH.2830410311 |
0.362 |
|
| 1992 |
Pilarski LM, Jensen GS. Monoclonal Circulating B Cells in Multiple Myeloma Hematology/Oncology Clinics of North America. 6: 297-322. DOI: 10.1016/s0889-8588(18)30346-0 |
0.318 |
|
| 1991 |
Jensen GS, Poppema S, Mant MJ, Pilarski LM. Transition in CD45 isoform expression during differentiation of normal and abnormal B cells. International Immunology. 1: 229-36. PMID 2535062 DOI: 10.1093/INTIMM/1.3.229 |
0.433 |
|
| 1991 |
Jensen GS, Andrews EJ, Mant MJ, Vergidis R, Ledbetter JA, Pilarski LM. Transitions in CD45 isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom's macroglobulinemia. American Journal of Hematology. 37: 20-30. PMID 1708944 DOI: 10.1002/AJH.2830370106 |
0.458 |
|
| 1991 |
Jensen G, Mant M, Belch A, Berenson J, Ruether B, Pilarski L. Selective expression of CD45 isoforms defines CALLA+ monoclonal B- lineage cells in peripheral blood from myeloma patients as late stage B cells Blood. 78: 711-719. DOI: 10.1182/blood.v78.3.711.bloodjournal783711 |
0.469 |
|
| 1991 |
Jensen G, Mant M, Belch A, Berenson J, Ruether B, Pilarski L. Selective expression of CD45 isoforms defines CALLA+ monoclonal B- lineage cells in peripheral blood from myeloma patients as late stage B cells Blood. 78: 711-719. DOI: 10.1182/BLOOD.V78.3.711.711 |
0.469 |
|
| 1990 |
Egerton M, Pruski E, Pilarski LM. Cell generation within human thymic subsets defined by selective expression of CD45 (T200) isoforms. Human Immunology. 27: 333-47. PMID 2138598 DOI: 10.1016/0198-8859(90)90084-3 |
0.36 |
|
| 1989 |
Kelly K, Pilarski L, Shortman K, Scollay R. CD4+ CD8+ cells are rare among in vitro activated mouse or human T lymphocytes. Cellular Immunology. 117: 414-24. PMID 3264216 DOI: 10.1016/0008-8749(88)90130-X |
0.499 |
|
| 1989 |
Pilarski LM, Andrews EJ, Serra HM, Ruether BA, Mant MJ. Comparative analysis of immunodeficiency in patients with monoclonal gammopathy of undetermined significance and patients with untreated multiple myeloma. Scandinavian Journal of Immunology. 29: 217-28. PMID 2784225 DOI: 10.1111/j.1365-3083.1989.tb01119.x |
0.416 |
|
| 1989 |
Pilarski LM, Andrews EJ, Serra HM, Ledbetter JA, Ruether BA, Mant MJ. Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenstrom's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance. American Journal of Hematology. 30: 53-60. PMID 2536515 DOI: 10.1002/AJH.2830300202 |
0.439 |
|
| 1989 |
Pilarski LM, Gillitzer R, Zola H, Shortman K, Scollay R. Definition of the thymic generative lineage by selective expression of high molecular weight isoforms of CD45 (T200). European Journal of Immunology. 19: 589-97. PMID 2525097 DOI: 10.1002/EJI.1830190403 |
0.362 |
|
| 1988 |
Serra HM, Mant MJ, Ruether BA, Ledbetter JA, Pilarski LM. Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients. Journal of Clinical Immunology. 8: 259-65. PMID 2970472 DOI: 10.1007/BF00916554 |
0.391 |
|
| 1987 |
Janowska-Wieczorek A, Andrews EJ, Khaliq A, Pilarski LM. Deficiency of mature B and T lymphocyte subsets in the blood of non-Hodgkin lymphoma patients. American Journal of Hematology. 26: 125-34. PMID 3499070 DOI: 10.1002/AJH.2830260203 |
0.356 |
|
| 1986 |
Pilarski LM, Andrews EJ, Mant MJ, Ruether BA. Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function. Journal of Clinical Immunology. 6: 491-501. PMID 3023434 DOI: 10.1007/BF00915255 |
0.335 |
|
| 1985 |
Pilarski L, Mant M, Ruether B, Carayanniotis G, Otto D, Krowka J. Abnormal clonogenic potential of T cells from multiple myeloma patients Blood. 66: 1266-1271. DOI: 10.1182/Blood.V66.6.1266.Bloodjournal6661266 |
0.415 |
|
| 1985 |
Pilarski L, Mant M, Ruether B, Carayanniotis G, Otto D, Krowka J. Abnormal clonogenic potential of T cells from multiple myeloma patients Blood. 66: 1266-1271. DOI: 10.1182/blood.v66.6.1266.1266 |
0.305 |
|
| 1985 |
Pilarski L, Mant M, Ruether B. Pre-B cells in peripheral blood of multiple myeloma patients Blood. 66: 416-422. DOI: 10.1182/Blood.V66.2.416.Bloodjournal662416 |
0.463 |
|
| 1985 |
Pilarski L, Mant M, Ruether B. Pre-B cells in peripheral blood of multiple myeloma patients Blood. 66: 416-422. DOI: 10.1182/blood.v66.2.416.416 |
0.363 |
|
| 1984 |
Pilarski LM, Mant MJ, Ruether BA, Belch A. Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients. The Journal of Clinical Investigation. 74: 1301-6. PMID 6332828 DOI: 10.1172/JCI111540 |
0.351 |
|
| Show low-probability matches. |